about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Imfinzi/treme­li­mum­ab com­bo scores As­traZeneca an­oth­er OS win — this time in liv­er can­cer

4 years ago
R&D

Bay­er breaks off Covid-19 vac­cine man­u­fac­tur­ing pact as Cure­Vac piv­ots to sec­ond-gen work — re­port

4 years ago
Coronavirus
Manufacturing

Bris­tol My­ers wants to pull out of its Abrax­ane deal in Chi­na. BeiGene says no way

4 years ago
Deals
China

GSK tan­goes with pri­vate eq­ui­ty play­ers to ex­plore $54B sale of con­sumer unit in­stead of IPO — re­port

4 years ago
Deals

On a quest to chal­lenge No­vo Nordisk in obe­si­ty, transpa­cif­ic start­up picks up $70M — and a pair of sea­soned ex­ecs

4 years ago
People
Financing

Top Sanofi vac­cine ex­ecs, Bris­tol My­ers vet chart new path for IG­M's an­ti­bod­ies in in­fec­tious dis­eases, au­toim­mu­ni­ty

4 years ago
People

Draw­ing Shire par­al­lel, Flem­ming Ørn­skov mulls IPO for Gal­der­ma; Rei­s­tone shows re­sults from eczema study with JAK1 ...

4 years ago
News Briefing

C4 co-founder re­signs as Dana-Far­ber trustee in the wake of new con­flict of in­ter­est poli­cies — re­port

4 years ago
R&D

Lat­est news: An­oth­er Alzheimer's 'break­through'?; GSK de­camps from icon­ic HQ; Red light in off-the-shelf CAR-T; ...

4 years ago
Weekly

Sanofi, Mod­er­na beef up the case for giv­ing flu, Covid-19 vac­cines to el­der­ly in the same vis­it

4 years ago
R&D
Coronavirus

Tiny play­er picks up $30M to go af­ter CAR-T's biggest chal­lenges

4 years ago
Financing
Startups

Take­da flash­es red light on 'break­through' nar­colep­sy drug af­ter PhII tri­als turned up mys­te­ri­ous safe­ty sig­nal

4 years ago
R&D

Un­fazed by OS flop, Zai Lab eyes im­mi­nent Chi­na fil­ing for Macro­Gen­ic­s' HER2 drug

4 years ago
R&D
China

Medicxi co-founder David Grainger gets his oth­er foot in Centes­sa's door as chief in­no­va­tion of­fi­cer

4 years ago
People

Long­time NIH di­rec­tor Fran­cis Collins re­signs to make room for 'new vi­sion'

4 years ago
People

Mer­ck shakes hands with Ac­celeron; Fi­nal­ly, a pill for Covid-19; The past and fu­ture of con­tract re­search; and more

4 years ago
Weekly

Black­list Chi­nese ge­net­ic se­quenc­ing com­pa­nies, law­mak­ers ar­gue — cit­ing po­ten­tial for 'bioweapons,' na­tion­al ...

4 years ago
China

The $165M im­munol­o­gy start­up Sheila Gu­jrathi bet on af­ter Re­cep­tos, Gos­samer is shoot­ing for an IPO

4 years ago
Financing

Ab­b­Vie clos­es in on Bio­haven with new mi­graine pre­ven­tion OK for oral CGRP drug

4 years ago
Pharma
FDA+

I-Mab in talks about deals, stake sale to build on $3B Ab­b­Vie al­liance — Bloomberg

4 years ago
Deals
China

As­traZeneca wa­gers on $500M buy­out, plucks PhI­II drug for Alex­ion’s rare dis­ease pipeline — and jumps straight ...

4 years ago
Deals

NIH spot­lights trio of aca­d­e­m­ic teams chas­ing af­ter 'pan-coro­n­avirus' vac­cines

4 years ago
Discovery

Bank­ing on in­te­grase in­hibitors as HIV cor­ner­stone, Vi­iV bags 3rd-gen­er­a­tion com­pound from Sh­iono­gi

4 years ago
Deals

Seiz­ing Aduhelm prece­dent, Bio­gen, Ei­sai get the ball rolling on an­oth­er ac­cel­er­at­ed Alzheimer's ap­proval

4 years ago
FDA+
First page Previous page 43444546474849 Next page Last page
A service from the Financial Times